Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China

BACKGROUND: Nab-paclitaxel plus gemcitabine (AG) has resulted in higher tumor response and survival rates for metastatic or advanced pancreatic ductal adenocarcinoma (PDAC) compared with gemcitabine (GEM) alone. AIM: To examine the feasibility and safety of AG adjuvant chemotherapy of resectable PDA...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:World J Clin Cases
Autori principali: Yin, Zhu-Zeng, Zhao, Zhi-Ming, Tang, Wen-Bo, Jiang, Nan, Zhang, Ke-Di, Song, Yu-Yao, Wang, Yang, Li, Cheng-Gang, Gao, Yuan-Xing, Liu, Rong
Natura: Artigo
Lingua:Inglês
Pubblicazione: Baishideng Publishing Group Inc 2020
Soggetti:
Retrospective Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7360710/
https://ncbi.nlm.nih.gov/pubmed/32742988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v8.i13.2778
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi